PTC Therapeutics, Inc. (PTCT)

NASDAQ • Healthcare

$64.7

+$2.14 (+3.4%)

Market closed

Last close at October 9, 2026 at 20:00 UTC

Open$62.52

Day Range$62.2 - $64.73

Avg. Volume (3M)1.3M

Market Cap$5.3B

52 Week Range

$61.23$90.87

Next EarningsIn 24 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$360.5M100%

Gross Profitminus cost of goods$340.5M94%

Operating Incomeminus R&D and overhead$148.9M41%

Net Incomeminus taxes and the rest$83.4M23%

In plain terms: out of every $100 in revenue, PTC Therapeutics, Inc. keeps $23 as net profit.

Fundamentals & Financials

Revenue (TTM)

$1B

Net Income (TTM)

-$38.3M

EPS (TTM)

-$0.49

ROA (TTM)

-1.18%

Current Ratio

3.39

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+22.4%Q3 2025-$0.83

+116.8%Q4 2025$0.2

-695.2%Q1 2026-$1.67

+93.3%Q2 2026-$0.03

+289.3%Q3 2026$0.92

Nov 3

in 24 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +289.3%

PTC Therapeutics’ revenue more than doubled year over year in the second fiscal quarter of 2026, as reported July 30, with revenue up 101.5% to roughly $360.5 million from about $178.9 million a year ago. Gross profit came in at around $340.6 million, translating to a gross margin of roughly 95%. The company generated operating cash flow of about $129.1 million during the quarter. For the next period, consensus calls for EPS of $0.28 on revenue of $302.3 million.

Next report — what to expect

PTC Therapeutics, Inc. (PTCT) is set to report earnings on November 3, 2026. Wall Street is expecting EPS of $0.292 on revenue of $303.9 million. For trailing context, revenue grew +101.5% year over year last quarter. PTCT has beaten EPS in 7 of 8 most recent quarters.

View full earnings history

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc. develops and commercializes medicines for rare genetic disorders as a biotechnology company listed on the NASDAQ Global Select Market under PTCT. Its portfolio spans approved and partnered therapies as well as pipeline programs, and it recorded $1.7 billion in revenue in FY2025.

Name

PTC Therapeutics, Inc.

CEO

Matthew Klein

Website

www.ptcbio.com

Industry

Healthcare

Year Founded

1998

Employees

991

Today's Snapshot

AI-generated

The day ended with PTCT 3.4% higher at 64.70, in line with a firmer sector.

Trading Volume

Below 10d avg (1.2M)

1.1M

vs S&P 500 Today

Outperforming Market

+2.83%

Updated: October 9, 2026 at 20:19 UTC

PTCT Headlines

Analysts Maintain Moderate Buy on PWR and PTC

April 9, 2026

4 min read

View All News

Technical Indicators

1 Buy3 Neutral4 Sell

PTCT is positioned below several intermediate and long-term averages even as very short-term moving averages sit close to the price, creating a conflicted profile that favors the downside. Momentum measures are muted with RSI in the mid-40s and MACD near neutral, while ADX near 19 points to a lack of strong trend. On-balance volume shows selling pressure and ATR indicates moderate intraday variability of roughly two dollars. The classic pivot sits below the current price, offering nearby support. Technical takeaway: Sell — price remains under longer-term averages with volume pressure present.

All signals